Eric K Rowinsky
CIK 1318886 · Chief Medical Officer · last filed 2026-06-11
Eric K Rowinsky is a Chief Medical Officer who has filed 82 SEC Form 4 insider transactions across 11 companies since 2007. The most recent filing, for BIIB, was dated Jun 11, 2026. Across all open-market trades the lifetime net is −$13.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $7.0M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$7.02M
11
82
-$13.07M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BIIB | Director | 25,844 | $205.61 | $5.31M | -$12.52M | 24 | 2026-06-11 |
| VSTM | Director | 54,666 | $6.23 | $340.6K | $7.7K | 12 | 2026-05-26 |
| FBIOP | Director | 68,797 | $18.76 | $1.29M | -$117.1K | 8 | 2024-01-03 |
| NAVIDEA BIOPHARMACEUTICALS, INC. (NAVB) Delisted | Director | 17,072 | $0.00 | $2 | $0 | 11 | 2018-02-22 |
| FBIO | Director | 23,333 | $3.39 | $79.1K | $0 | 2 | 2017-01-24 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | — | — | — | $0 | 3 | 2016-06-22 |
| STEMLINE THERAPEUTICS INC (STML) Delisted | Chief Medical Officer | 143,688 | — | — | -$479.5K | 6 | 2015-04-28 |
| Fortress Biotech, Inc. (CNDO) Delisted | Director | 150,000 | — | — | $0 | 4 | 2015-03-16 |
| NAVIDEA BIOPHARMACEUTICALS, INC. (NEOP) Delisted | Director | 15,000 | — | — | $38.2K | 2 | 2011-08-23 |
| Savara Inc (ANX) Delisted | Director | — | — | — | $0 | 4 | 2010-07-01 |
| IMCLONE SYSTEMS INC (IMCL) Delisted | SVP, Chief Medical Officer | 0 | — | — | $0 | 4 | 2008-11-24 |
Recent Filings
82 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-11 | BIIB | Grant (A) | +1,505 | $0 | EDGAR |
| 2026-05-26 | VSTM | Grant (A) | +36,000 | $0 | EDGAR |
| 2025-06-18 | BIIB | Grant (A) | +2,370 | $0 | EDGAR |
| 2025-05-27 | VSTM | Grant (A) | +8,333 | $0 | EDGAR |
| 2024-06-25 | BIIB | Grant (A) | +1,340 | $0 | EDGAR |
| 2024-06-20 | VSTM | Grant (A) | +8,333 | $0 | EDGAR |
| 2024-03-13 | VSTM | Mixed | — | $0 | EDGAR |
| 2024-02-20 | BIIB | Buy (P) | +455 | $101.3K | EDGAR |
| 2024-01-24 | VSTM | Buy (P) | +2,000 | $7.7K | EDGAR |
| 2024-01-03 | FBIOP | Grant (A) | +6,666 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.